Assess the Penumbra System in the Treatment of Acute Stroke
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as
an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator
(rtPA)in patients with acute ischemic stroke from large vessel occlusion in the brain. IV
rtPA is the only drug approved for the treatment of acute ischemic stroke but it does not
work very well in cases where the stroke is caused by a large vessel occlusion. The
hypothesis being tested is to determine if the addition of a treatment by a mechanical
thrombectomy device like the Penumbra System can improve the clinical outcome of the patient
over just using IV rtPA alone.